View ValuationMedpace Holdings 향후 성장Future 기준 점검 4/6Medpace Holdings (는) 각각 연간 9.4% 및 7.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 8.7% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 32.9% 로 예상됩니다.핵심 정보9.4%이익 성장률8.72%EPS 성장률Life Sciences 이익 성장0%매출 성장률7.6%향후 자기자본이익률32.86%애널리스트 커버리지Good마지막 업데이트08 Jul 2026최근 향후 성장 업데이트공시 • Apr 23Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2026Medpace Holdings, Inc. provided earnings guidance for the year 2026. For the year, the company forecasts revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income for full year 2026 is forecasted in the range of $487.0 million to $511.0 million. Based on forecasted 2026 revenue of $2.755 billion to $2.855 billion and GAAP net income of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50. This guidance assumes a full year 2026 tax rate of 19.0% to 20.0%, interest income of $27.5 million, foreign exchange rates as of March 31, 2026, and 29.2 million diluted weighted average shares outstanding.공시 • Feb 10Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year of 2026Medpace Holdings, Inc. provides earnings guidance for the full year of 2026. For the period, the company expects revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income is forecasted in the range of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50.공시 • Oct 23Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2025Medpace Holdings, Inc. provided earnings guidance for the full year 2025. The Company forecasts 2025 revenue in the range of $2.480 billion to $2.530 billion, representing growth of 17.6% to 20.0% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $431.0 million to $439.0 million. Diluted earnings per share (GAAP) is forecasted in the range of $14.60 to $14.86.공시 • Jul 22Medpace Holdings, Inc. Updates Earnings Guidance for the Full Year 2025Medpace Holdings, Inc. updated earnings guidance for the full year 2025. For the year company expects revenue in the range of $2.420 billion to $2.520 billion, representing growth of 14.7% to 19.5% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $405.0 million to $428.0 million. Based on forecasted 2025 revenue of $2.420 billion to $2.520 billion and GAAP net income of $405.0 million to $428.0 million, diluted earnings per share (GAAP) is forecasted in the range of $13.76 to $14.53.공시 • Apr 22Medpace Holdings, Inc. Provides Earnings Guidance for 2025Medpace Holdings, Inc. provides earnings guidance for 2025. For the period, the Company forecasted 2025 revenue in the range of $2.140 billion to $2.240 billion, representing growth of 1.5% to 6.2% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $378.0 million to $402.0 million. Based on forecasted 2025 revenue of $2.140 billion to $2.240 billion and GAAP net income of $378.0 million to $402.0 million, diluted earnings per share (GAAP) is forecasted in the range of $12.26 to $13.04.공시 • Feb 11Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2025Medpace Holdings, Inc. provided earnings guidance for the year 2025. For the period, the company expects revenue in the range of $2.110 billion to $2.210 billion, representing growth of 0.0% to 4.8% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $378.0 million to $402.0 million. Based on forecasted 2025 revenue of $2.110 billion to $2.210 billion and GAAP net income of $378.0 million to $402.0 million, diluted earnings per share (GAAP) is forecasted in the range of $11.93 to $12.69.모든 업데이트 보기Recent updates공시 • Jun 17Medpace Holdings, Inc. to Report Q2, 2026 Results on Jul 22, 2026Medpace Holdings, Inc. announced that they will report Q2, 2026 results After-Market on Jul 22, 2026공시 • Jun 06Medpace Holdings, Inc. Announces Appointment of Brad W. Hansman to Executive Vice President, Operations, Effective June 1, 2026Effective June 1, 2026, Medpace Holdings, Inc. appointed Brad W. Hansman, age 43, to the position of Executive Vice President, Operations. In this role, Mr. Hansman shall perform the functions of the Company’s principal operating officer along with Susan E. Burwig, the Company’s Executive Vice President, Operations. Mr. Hansman joined the Company in April 2011 in Finance & Accounting and held various roles in Finance until July 2015. Since August 2015, Mr. Hansman has held various key leadership roles in operations including Executive Director, Vice President, and Senior Vice President overseeing study start-up, logistics, regulatory affairs, and medical writing. Prior to joining the Company, Mr. Hansman worked for Joseph Decosimo & Company, LLC as an Audit Supervisor from July 2008 to March 2011. Mr. Hansman started his career at Macy’s, Inc. where he held various auditor positions from July 2006 to June 2008. Mr. Hansman received his Bachelor of Business Administration in Accounting from Eastern Kentucky University and is a Certified Public Accountant (inactive). Mr. Hansman does not hold any public company directorships.공시 • Apr 23Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2026Medpace Holdings, Inc. provided earnings guidance for the year 2026. For the year, the company forecasts revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income for full year 2026 is forecasted in the range of $487.0 million to $511.0 million. Based on forecasted 2026 revenue of $2.755 billion to $2.855 billion and GAAP net income of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50. This guidance assumes a full year 2026 tax rate of 19.0% to 20.0%, interest income of $27.5 million, foreign exchange rates as of March 31, 2026, and 29.2 million diluted weighted average shares outstanding.공시 • Mar 25Medpace Holdings, Inc. to Report Q1, 2026 Results on Apr 22, 2026Medpace Holdings, Inc. announced that they will report Q1, 2026 results After-Market on Apr 22, 2026공시 • Mar 17Medpace Holdings, Inc., Annual General Meeting, May 15, 2026Medpace Holdings, Inc., Annual General Meeting, May 15, 2026.공시 • Feb 10Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year of 2026Medpace Holdings, Inc. provides earnings guidance for the full year of 2026. For the period, the company expects revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income is forecasted in the range of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50.공시 • Jan 06Medpace Holdings, Inc. to Report Q4, 2025 Results on Feb 09, 2026Medpace Holdings, Inc. announced that they will report Q4, 2025 results After-Market on Feb 09, 2026공시 • Oct 23Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2025Medpace Holdings, Inc. provided earnings guidance for the full year 2025. The Company forecasts 2025 revenue in the range of $2.480 billion to $2.530 billion, representing growth of 17.6% to 20.0% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $431.0 million to $439.0 million. Diluted earnings per share (GAAP) is forecasted in the range of $14.60 to $14.86.공시 • Sep 24Medpace Holdings, Inc. to Report Q3, 2025 Results on Oct 22, 2025Medpace Holdings, Inc. announced that they will report Q3, 2025 results After-Market on Oct 22, 2025공시 • Jul 22Medpace Holdings, Inc. Updates Earnings Guidance for the Full Year 2025Medpace Holdings, Inc. updated earnings guidance for the full year 2025. For the year company expects revenue in the range of $2.420 billion to $2.520 billion, representing growth of 14.7% to 19.5% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $405.0 million to $428.0 million. Based on forecasted 2025 revenue of $2.420 billion to $2.520 billion and GAAP net income of $405.0 million to $428.0 million, diluted earnings per share (GAAP) is forecasted in the range of $13.76 to $14.53.공시 • Jun 24Medpace Holdings, Inc. to Report Q2, 2025 Results on Jul 21, 2025Medpace Holdings, Inc. announced that they will report Q2, 2025 results After-Market on Jul 21, 2025공시 • Apr 22Medpace Holdings, Inc. Provides Earnings Guidance for 2025Medpace Holdings, Inc. provides earnings guidance for 2025. For the period, the Company forecasted 2025 revenue in the range of $2.140 billion to $2.240 billion, representing growth of 1.5% to 6.2% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $378.0 million to $402.0 million. Based on forecasted 2025 revenue of $2.140 billion to $2.240 billion and GAAP net income of $378.0 million to $402.0 million, diluted earnings per share (GAAP) is forecasted in the range of $12.26 to $13.04.공시 • Apr 03Medpace Holdings, Inc., Annual General Meeting, May 16, 2025Medpace Holdings, Inc., Annual General Meeting, May 16, 2025.공시 • Mar 19Medpace Holdings, Inc. to Report Q1, 2025 Results on Apr 21, 2025Medpace Holdings, Inc. announced that they will report Q1, 2025 results After-Market on Apr 21, 2025공시 • Feb 11Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2025Medpace Holdings, Inc. provided earnings guidance for the year 2025. For the period, the company expects revenue in the range of $2.110 billion to $2.210 billion, representing growth of 0.0% to 4.8% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $378.0 million to $402.0 million. Based on forecasted 2025 revenue of $2.110 billion to $2.210 billion and GAAP net income of $378.0 million to $402.0 million, diluted earnings per share (GAAP) is forecasted in the range of $11.93 to $12.69.공시 • Jan 03Medpace Holdings, Inc. to Report Q4, 2024 Results on Feb 10, 2025Medpace Holdings, Inc. announced that they will report Q4, 2024 results After-Market on Feb 10, 2025공시 • Oct 22Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024Medpace Holdings, Inc. provided earnings guidance for the full year 2024. For the period, the company expects revenue in the range of $2.090 billion to $2.130 billion, representing growth of 10.8% to 12.9% over 2023 revenue of $1.886 billion. GAAP net income is forecasted in the range of $376.0 million to $388.0 million. Diluted earnings per share (GAAP) is forecasted in the range of $11.71 to $12.09.공시 • Sep 26Medpace Holdings, Inc. to Report Q3, 2024 Results on Oct 21, 2024Medpace Holdings, Inc. announced that they will report Q3, 2024 results After-Market on Oct 21, 2024Reported Earnings • Jul 23Second quarter 2024 earnings released: EPS: US$2.85 (vs US$2.00 in 2Q 2023)Second quarter 2024 results: EPS: US$2.85 (up from US$2.00 in 2Q 2023). Revenue: US$528.1m (up 15% from 2Q 2023). Net income: US$88.4m (up 45% from 2Q 2023). Profit margin: 17% (up from 13% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Global Life Sciences industry. Over the last 3 years on average, earnings per share has increased by 28% per year whereas the company’s share price has increased by 30% per year.공시 • Jul 23Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024Medpace Holdings, Inc. provided earnings guidance for the full year 2024. The company forecasts 2024 revenue in the range of $2.125 billion to $2.175 billion, representing growth of 12.7% to 15.3% over 2023 revenue of $1.886 billion. GAAP net income for full year 2024 is forecasted in the range of $361.0 million to $383.0 million. Based on forecasted 2024 revenue of $2.125 billion to $2.175 billion and GAAP net income of $361.0 million to $383.0 million, diluted earnings per share (GAAP) is forecasted in the range of $11.24 to $11.93. This guidance assumes a full year 2024 tax rate of 15.0% to 16.0%, interest income of $24.0 million, and 32.1 million diluted shares outstanding.공시 • Jun 27Medpace Holdings, Inc. to Report Q2, 2024 Results on Jul 22, 2024Medpace Holdings, Inc. announced that they will report Q2, 2024 results After-Market on Jul 22, 2024Reported Earnings • Apr 23First quarter 2024 earnings released: EPS: US$3.33 (vs US$2.35 in 1Q 2023)First quarter 2024 results: EPS: US$3.33 (up from US$2.35 in 1Q 2023). Revenue: US$511.0m (up 18% from 1Q 2023). Net income: US$102.6m (up 41% from 1Q 2023). Profit margin: 20% (up from 17% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 7.6% growth forecast for the Global Life Sciences industry. Over the last 3 years on average, earnings per share has increased by 28% per year whereas the company’s share price has increased by 24% per year.공시 • Apr 23Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024Medpace Holdings, Inc. provided earnings guidance for the full year 2024. The Company forecasts 2024 revenue in the range of $2.150 billion to $2.200 billion, representing growth of 14.0% to 16.7% over 2023 revenue of $1.886 billion. GAAP net income for full year 2024 is forecasted in the range of $347.0 million to $369.0 million, diluted earnings per share (GAAP) is forecasted in the range of $10.79 to $11.47.Board Change • Apr 15Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Director Femida Gwadry-Sridhar was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Apr 04Medpace Holdings, Inc., Annual General Meeting, May 17, 2024Medpace Holdings, Inc., Annual General Meeting, May 17, 2024, at 09:00 US Eastern Standard Time. Agenda: To elect Fred B. Davenport, Jr. and Cornelius P. McCarthy III as Class II Directors to serve until the 2027 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified; to ratify the appointment of Deloitte & Touche LLP as company independent registered public accounting firm for the fiscal year ending December 31, 2024; to conduct an advisory vote to approve compensation for our named executive officers; to approve an amendment to the company's Amended and Restated Certificate of Incorporation to begin phasing out the company's classified Board of Directors so that directors up for election at and after the 2025 Annual Meeting of Stockholders will be elected annually; and to transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment of the Annual Meeting by or at the direction of the Board of Directors of the company.공시 • Mar 29Medpace Holdings, Inc. to Report Q1, 2024 Results on Apr 22, 2024Medpace Holdings, Inc. announced that they will report Q1, 2024 results on Apr 22, 2024Board Change • Dec 05Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Director Femida Gwadry-Sridhar was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Oct 25Medpace Holdings, Inc. Provides Earnings Guidance for the Fiscal Year 2023 and 2024Medpace Holdings, Inc. provided earnings guidance for the fiscal year 2023 and 2024. For the year 2023, the company expects revenue in the range of $1.870 billion to $1.890 billion, representing growth of 28.1% to 29.5% over 2022 revenue of $1.460 billion. GAAP net income for full year 2023 is forecasted in the range of $272.0 million to $276.0 million and diluted earnings per share (GAAP) is forecasted in the range of $8.54 to $8.66.For the year 2024, the company expects revenue in the range of $2.150 billion to $2.200 billion.공시 • Sep 27Medpace Holdings, Inc. to Report Q3, 2023 Results on Oct 23, 2023Medpace Holdings, Inc. announced that they will report Q3, 2023 results on Oct 23, 2023Board Change • Sep 22Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Director Femida Gwadry-Sridhar was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Jul 26Second quarter 2023 earnings released: EPS: US$2.00 (vs US$1.52 in 2Q 2022)Second quarter 2023 results: EPS: US$2.00 (up from US$1.52 in 2Q 2022). Revenue: US$460.9m (up 31% from 2Q 2022). Net income: US$61.1m (up 24% from 2Q 2022). Profit margin: 13% (in line with 2Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Global Life Sciences industry. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth.공시 • Jul 25Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2023Medpace Holdings, Inc. provided earnings guidance for the full year 2023. The company forecasts 2023 revenue in the range of $1.840 billion to $1.880 billion, representing growth of 26.0% to 28.8% over 2022 revenue of $1.460 billion. GAAP net income for full year 2023 is forecasted in the range of $256.0 million to $271.0 million. Based on forecasted 2023 revenue of $1.840 billion to $1.880 billion and GAAP net income of $256.0 million to $271.0 million, diluted earnings per share (GAAP) is forecasted in the range of $8.04 to $8.50.Board Change • Jul 14Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Director Femida Gwadry-Sridhar was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Jul 06Medpace Holdings, Inc. to Report Q2, 2023 Results on Jul 24, 2023Medpace Holdings, Inc. announced that they will report Q2, 2023 results After-Market on Jul 24, 2023공시 • Jun 25+ 1 more updateMedpace Holdings, Inc.(NasdaqGS:MEDP) dropped from Russell 2000 Growth-Defensive IndexMedpace Holdings, Inc.(NasdaqGS:MEDP) dropped from Russell 2000 Growth-Defensive IndexBoard Change • May 12Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Director Femida Gwadry-Sridhar was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 28First quarter 2023 earnings released: EPS: US$2.35 (vs US$1.76 in 1Q 2022)First quarter 2023 results: EPS: US$2.35 (up from US$1.76 in 1Q 2022). Revenue: US$434.1m (up 31% from 1Q 2022). Net income: US$72.8m (up 19% from 1Q 2022). Profit margin: 17% (down from 19% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Global Life Sciences industry. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.Board Change • Apr 26Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Director Femida Gwadry-Sridhar was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Feb 14Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2023Medpace Holdings, Inc. provided earnings guidance for the year 2023. For the year, the company expects revenue in the range of $1.690 billion to $1.750 billion, representing growth of 15.8% to 19.9% over 2022 revenue of $1.460 billion. GAAP net income is forecasted in the range of $245.0 million to $265.0 million. Based on forecasted revenue of $1.690 billion to $1.750 billion and GAAP net income of $245.0 million to $265.0 million, diluted earnings per share (GAAP) is forecasted in the range of $7.53 to $8.14.Board Change • Jan 27Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Director Femida Gwadry-Sridhar was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Jan 05Medpace Holdings, Inc. to Report Fiscal Year 2022 Results on Feb 13, 2023Medpace Holdings, Inc. announced that they will report fiscal year 2022 results at 4:00 PM, US Eastern Standard Time on Feb 13, 2023공시 • Jan 04Medpace Holdings, Inc. Announces Resignation of Thomas C. King to BoardOn December 31, 2022, Thomas C. King, a member of the Board of Directors of Medpace Holdings, Inc. notified the Company of his resignation from the Board, effective as of December 31, 2022. Mr. King’s resignation did not result from any disagreement with the Company on any matter relating to its operations, policies or practices.Board Change • Dec 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. Independent Director Thomas King was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Dec 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. Independent Director Thomas King was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • Nov 18CFO & Treasurer recently sold Mex$8.8m worth of stockOn the 16th of November, Kevin Brady sold around 2k shares on-market at roughly Mex$4,423 per share. This transaction amounted to 40% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Kevin's only on-market trade for the last 12 months.Board Change • Nov 17Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. Independent Director Thomas King was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Nov 01Investor sentiment improved over the past weekAfter last week's 37% share price gain to Mex$4,326, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 29x in the Life Sciences industry globally. Total returns to shareholders of 202% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at Mex$6,096 per share.Reported Earnings • Oct 26Third quarter 2022 earnings released: EPS: US$2.13 (vs US$1.35 in 3Q 2021)Third quarter 2022 results: EPS: US$2.13 (up from US$1.35 in 3Q 2021). Revenue: US$383.7m (up 30% from 3Q 2021). Net income: US$66.0m (up 36% from 3Q 2021). Profit margin: 17% (in line with 3Q 2021). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Global Life Sciences industry. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 44% per year, which means it is tracking significantly ahead of earnings growth.Board Change • Oct 25Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. Independent Director Thomas King was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Recent Insider Transactions • Sep 23Chairman & CEO recently bought Mex$292m worth of stockOn the 20th of September, August Troendle bought around 94k shares on-market at roughly Mex$3,105 per share. This transaction amounted to 1.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. August has been a buyer over the last 12 months, purchasing a net total of Mex$500m worth in shares.Board Change • Sep 22Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Director Thomas King was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • Sep 14Chairman & CEO recently bought Mex$207m worth of stockOn the 12th of September, August Troendle bought around 63k shares on-market at roughly Mex$3,316 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was August's only on-market trade for the last 12 months.Valuation Update With 7 Day Price Move • Sep 02Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to Mex$2,914, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 30x in the Life Sciences industry globally. Total returns to shareholders of 88% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at Mex$3,750 per share.Board Change • Aug 18Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Director Thomas King was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Jul 26Second quarter 2022 earnings released: EPS: US$1.52 (vs US$1.11 in 2Q 2021)Second quarter 2022 results: EPS: US$1.52 (up from US$1.11 in 2Q 2021). Revenue: US$351.2m (up 26% from 2Q 2021). Net income: US$49.4m (up 24% from 2Q 2021). Profit margin: 14% (in line with 2Q 2021). Over the next year, revenue is forecast to grow 14%, compared to a 12% growth forecast for the industry in Mexico. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth.Board Change • Jul 25Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Director Thomas King was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Jun 28Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Director Thomas King was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Jun 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Director Thomas King was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Feb 25Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to Mex$3,022, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 34x in the Life Sciences industry globally. Total loss to shareholders of 11% over the past year. Simply Wall St's valuation model estimates the intrinsic value at Mex$5,635 per share.Recent Insider Transactions • Feb 24Lead Independent Director recently bought Mex$1.5m worth of stockOn the 17th of February, Fred Davenport bought around 500 shares on-market at roughly Mex$2,959 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold Mex$20m more in shares than they bought in the last 12 months.Reported Earnings • Feb 16Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: US$5.07 (up from US$4.07 in FY 2020). Revenue: US$1.14b (up 23% from FY 2020). Net income: US$181.8m (up 26% from FY 2020). Profit margin: 16% (in line with FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 25%, compared to a 16% growth forecast for the pharmaceuticals industry in Mexico.Valuation Update With 7 Day Price Move • Nov 05Investor sentiment improved over the past weekAfter last week's 21% share price gain to Mex$4,630, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 45x in the Life Sciences industry globally. Simply Wall St's valuation model estimates the intrinsic value at Mex$3,700 per share.Reported Earnings • Oct 26Third quarter 2021 earnings released: EPS US$1.36 (vs US$1.16 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: US$295.6m (up 28% from 3Q 2020). Net income: US$48.6m (up 18% from 3Q 2020). Profit margin: 16% (down from 18% in 3Q 2020). The decrease in margin was driven by higher expenses.Reported Earnings • Jul 28Second quarter 2021 earnings released: EPS US$1.11 (vs US$0.68 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$278.3m (up 36% from 2Q 2020). Net income: US$39.9m (up 66% from 2Q 2020). Profit margin: 14% (up from 12% in 2Q 2020). The increase in margin was driven by higher revenue.Recent Insider Transactions • Mar 12Executive Vice President of Operations recently sold Mex$22m worth of stockOn the 3rd of March, Susan Burwig sold around 6k shares on-market at roughly Mex$3,486 per share. This was the largest sale by an insider in the last 3 months. Susan has been a seller over the last 12 months, reducing personal holdings by Mex$58m.Recent Insider Transactions • Mar 06Executive Vice President of Operations recently sold Mex$22m worth of stockOn the 3rd of March, Susan Burwig sold around 6k shares on-market at roughly Mex$3,486 per share. This was the largest sale by an insider in the last 3 months. Susan has been a seller over the last 12 months, reducing personal holdings by Mex$58m.Reported Earnings • Feb 19Full year 2020 earnings released: EPS US$4.07 (vs US$2.79 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: US$925.9m (up 7.5% from FY 2019). Net income: US$144.9m (up 45% from FY 2019). Profit margin: 16% (up from 12% in FY 2019). The increase in margin was driven by higher revenue.Analyst Estimate Surprise Post Earnings • Feb 19Revenue beats expectationsRevenue exceeded analyst estimates by 1.5%. Over the next year, revenue is forecast to grow 23%, compared to a 44% growth forecast for the Life Sciences industry in Mexico.Valuation Update With 7 Day Price Move • Feb 13Investor sentiment improved over the past weekAfter last week's 21% share price gain to US$3,345, the stock is trading at a trailing P/E ratio of 48.2x, up from the previous P/E ratio of 39.9x. This compares to an average P/E of 55x in the Life Sciences industry. Total returns to shareholders over the past year are 106%.이익 및 매출 성장 예측BMV:MEDP * - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20283,258602743796912/31/20272,9495406296741212/31/20262,774493569613123/31/20262,678460711739N/A12/31/20252,530451682713N/A9/30/20252,358433677711N/A6/30/20252,232418580614N/A3/31/20252,157416541582N/A12/31/20242,109404572609N/A9/30/20242,071366536575N/A6/30/20242,030340503540N/A3/31/20241,963312473506N/A12/31/20231,886283397433N/A9/30/20231,782273378414N/A6/30/20231,673268373408N/A3/31/20231,563257385422N/A12/31/20221,460245351388N/A9/30/20221,374227286322N/A6/30/20221,286209250286N/A3/31/20221,213199221252N/A12/31/20211,142181235263N/A9/30/20211,094182271298N/A6/30/20211,028175256285N/A3/31/2021955159235267N/A12/31/2020926145227259N/A9/30/2020896124181210N/A6/30/2020882107188215N/A3/31/2020891110196217N/A12/31/2019861100N/A202N/A9/30/201982393N/A184N/A6/30/201978688N/A173N/A3/31/201974278N/A167N/A12/31/201870573N/A157N/A9/30/201861261N/A146N/A6/30/201853152N/A132N/A3/31/201845645N/A121N/A12/31/201738639N/A97N/A9/30/201738228N/A98N/A6/30/201737923N/A101N/A3/31/201737718N/A78N/A12/31/201637113N/A92N/A9/30/20163615N/A91N/A6/30/20163480N/A80N/A3/31/2016332-5N/A94N/A12/31/2015320-9N/A86N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: MEDP * 의 연간 예상 수익 증가율(9.4%)이 saving rate(9%)보다 높습니다.수익 vs 시장: MEDP * 의 연간 수익(9.4%)이 MX 시장(9.3%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: MEDP * 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: MEDP * 의 수익(연간 7.6%)이 MX 시장(연간 6.4%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: MEDP * 의 수익(연간 7.6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: MEDP *의 자본 수익률은 3년 후 32.9%로 높을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/10 16:16종가2026/04/24 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Medpace Holdings, Inc.는 20명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Eric ColdwellBairdLuke SergottBarclaysSean DodgeBMO Capital Markets Equity Research17명의 분석가 더 보기
공시 • Apr 23Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2026Medpace Holdings, Inc. provided earnings guidance for the year 2026. For the year, the company forecasts revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income for full year 2026 is forecasted in the range of $487.0 million to $511.0 million. Based on forecasted 2026 revenue of $2.755 billion to $2.855 billion and GAAP net income of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50. This guidance assumes a full year 2026 tax rate of 19.0% to 20.0%, interest income of $27.5 million, foreign exchange rates as of March 31, 2026, and 29.2 million diluted weighted average shares outstanding.
공시 • Feb 10Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year of 2026Medpace Holdings, Inc. provides earnings guidance for the full year of 2026. For the period, the company expects revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income is forecasted in the range of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50.
공시 • Oct 23Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2025Medpace Holdings, Inc. provided earnings guidance for the full year 2025. The Company forecasts 2025 revenue in the range of $2.480 billion to $2.530 billion, representing growth of 17.6% to 20.0% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $431.0 million to $439.0 million. Diluted earnings per share (GAAP) is forecasted in the range of $14.60 to $14.86.
공시 • Jul 22Medpace Holdings, Inc. Updates Earnings Guidance for the Full Year 2025Medpace Holdings, Inc. updated earnings guidance for the full year 2025. For the year company expects revenue in the range of $2.420 billion to $2.520 billion, representing growth of 14.7% to 19.5% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $405.0 million to $428.0 million. Based on forecasted 2025 revenue of $2.420 billion to $2.520 billion and GAAP net income of $405.0 million to $428.0 million, diluted earnings per share (GAAP) is forecasted in the range of $13.76 to $14.53.
공시 • Apr 22Medpace Holdings, Inc. Provides Earnings Guidance for 2025Medpace Holdings, Inc. provides earnings guidance for 2025. For the period, the Company forecasted 2025 revenue in the range of $2.140 billion to $2.240 billion, representing growth of 1.5% to 6.2% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $378.0 million to $402.0 million. Based on forecasted 2025 revenue of $2.140 billion to $2.240 billion and GAAP net income of $378.0 million to $402.0 million, diluted earnings per share (GAAP) is forecasted in the range of $12.26 to $13.04.
공시 • Feb 11Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2025Medpace Holdings, Inc. provided earnings guidance for the year 2025. For the period, the company expects revenue in the range of $2.110 billion to $2.210 billion, representing growth of 0.0% to 4.8% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $378.0 million to $402.0 million. Based on forecasted 2025 revenue of $2.110 billion to $2.210 billion and GAAP net income of $378.0 million to $402.0 million, diluted earnings per share (GAAP) is forecasted in the range of $11.93 to $12.69.
공시 • Jun 17Medpace Holdings, Inc. to Report Q2, 2026 Results on Jul 22, 2026Medpace Holdings, Inc. announced that they will report Q2, 2026 results After-Market on Jul 22, 2026
공시 • Jun 06Medpace Holdings, Inc. Announces Appointment of Brad W. Hansman to Executive Vice President, Operations, Effective June 1, 2026Effective June 1, 2026, Medpace Holdings, Inc. appointed Brad W. Hansman, age 43, to the position of Executive Vice President, Operations. In this role, Mr. Hansman shall perform the functions of the Company’s principal operating officer along with Susan E. Burwig, the Company’s Executive Vice President, Operations. Mr. Hansman joined the Company in April 2011 in Finance & Accounting and held various roles in Finance until July 2015. Since August 2015, Mr. Hansman has held various key leadership roles in operations including Executive Director, Vice President, and Senior Vice President overseeing study start-up, logistics, regulatory affairs, and medical writing. Prior to joining the Company, Mr. Hansman worked for Joseph Decosimo & Company, LLC as an Audit Supervisor from July 2008 to March 2011. Mr. Hansman started his career at Macy’s, Inc. where he held various auditor positions from July 2006 to June 2008. Mr. Hansman received his Bachelor of Business Administration in Accounting from Eastern Kentucky University and is a Certified Public Accountant (inactive). Mr. Hansman does not hold any public company directorships.
공시 • Apr 23Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2026Medpace Holdings, Inc. provided earnings guidance for the year 2026. For the year, the company forecasts revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income for full year 2026 is forecasted in the range of $487.0 million to $511.0 million. Based on forecasted 2026 revenue of $2.755 billion to $2.855 billion and GAAP net income of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50. This guidance assumes a full year 2026 tax rate of 19.0% to 20.0%, interest income of $27.5 million, foreign exchange rates as of March 31, 2026, and 29.2 million diluted weighted average shares outstanding.
공시 • Mar 25Medpace Holdings, Inc. to Report Q1, 2026 Results on Apr 22, 2026Medpace Holdings, Inc. announced that they will report Q1, 2026 results After-Market on Apr 22, 2026
공시 • Mar 17Medpace Holdings, Inc., Annual General Meeting, May 15, 2026Medpace Holdings, Inc., Annual General Meeting, May 15, 2026.
공시 • Feb 10Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year of 2026Medpace Holdings, Inc. provides earnings guidance for the full year of 2026. For the period, the company expects revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income is forecasted in the range of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50.
공시 • Jan 06Medpace Holdings, Inc. to Report Q4, 2025 Results on Feb 09, 2026Medpace Holdings, Inc. announced that they will report Q4, 2025 results After-Market on Feb 09, 2026
공시 • Oct 23Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2025Medpace Holdings, Inc. provided earnings guidance for the full year 2025. The Company forecasts 2025 revenue in the range of $2.480 billion to $2.530 billion, representing growth of 17.6% to 20.0% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $431.0 million to $439.0 million. Diluted earnings per share (GAAP) is forecasted in the range of $14.60 to $14.86.
공시 • Sep 24Medpace Holdings, Inc. to Report Q3, 2025 Results on Oct 22, 2025Medpace Holdings, Inc. announced that they will report Q3, 2025 results After-Market on Oct 22, 2025
공시 • Jul 22Medpace Holdings, Inc. Updates Earnings Guidance for the Full Year 2025Medpace Holdings, Inc. updated earnings guidance for the full year 2025. For the year company expects revenue in the range of $2.420 billion to $2.520 billion, representing growth of 14.7% to 19.5% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $405.0 million to $428.0 million. Based on forecasted 2025 revenue of $2.420 billion to $2.520 billion and GAAP net income of $405.0 million to $428.0 million, diluted earnings per share (GAAP) is forecasted in the range of $13.76 to $14.53.
공시 • Jun 24Medpace Holdings, Inc. to Report Q2, 2025 Results on Jul 21, 2025Medpace Holdings, Inc. announced that they will report Q2, 2025 results After-Market on Jul 21, 2025
공시 • Apr 22Medpace Holdings, Inc. Provides Earnings Guidance for 2025Medpace Holdings, Inc. provides earnings guidance for 2025. For the period, the Company forecasted 2025 revenue in the range of $2.140 billion to $2.240 billion, representing growth of 1.5% to 6.2% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $378.0 million to $402.0 million. Based on forecasted 2025 revenue of $2.140 billion to $2.240 billion and GAAP net income of $378.0 million to $402.0 million, diluted earnings per share (GAAP) is forecasted in the range of $12.26 to $13.04.
공시 • Apr 03Medpace Holdings, Inc., Annual General Meeting, May 16, 2025Medpace Holdings, Inc., Annual General Meeting, May 16, 2025.
공시 • Mar 19Medpace Holdings, Inc. to Report Q1, 2025 Results on Apr 21, 2025Medpace Holdings, Inc. announced that they will report Q1, 2025 results After-Market on Apr 21, 2025
공시 • Feb 11Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2025Medpace Holdings, Inc. provided earnings guidance for the year 2025. For the period, the company expects revenue in the range of $2.110 billion to $2.210 billion, representing growth of 0.0% to 4.8% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $378.0 million to $402.0 million. Based on forecasted 2025 revenue of $2.110 billion to $2.210 billion and GAAP net income of $378.0 million to $402.0 million, diluted earnings per share (GAAP) is forecasted in the range of $11.93 to $12.69.
공시 • Jan 03Medpace Holdings, Inc. to Report Q4, 2024 Results on Feb 10, 2025Medpace Holdings, Inc. announced that they will report Q4, 2024 results After-Market on Feb 10, 2025
공시 • Oct 22Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024Medpace Holdings, Inc. provided earnings guidance for the full year 2024. For the period, the company expects revenue in the range of $2.090 billion to $2.130 billion, representing growth of 10.8% to 12.9% over 2023 revenue of $1.886 billion. GAAP net income is forecasted in the range of $376.0 million to $388.0 million. Diluted earnings per share (GAAP) is forecasted in the range of $11.71 to $12.09.
공시 • Sep 26Medpace Holdings, Inc. to Report Q3, 2024 Results on Oct 21, 2024Medpace Holdings, Inc. announced that they will report Q3, 2024 results After-Market on Oct 21, 2024
Reported Earnings • Jul 23Second quarter 2024 earnings released: EPS: US$2.85 (vs US$2.00 in 2Q 2023)Second quarter 2024 results: EPS: US$2.85 (up from US$2.00 in 2Q 2023). Revenue: US$528.1m (up 15% from 2Q 2023). Net income: US$88.4m (up 45% from 2Q 2023). Profit margin: 17% (up from 13% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Global Life Sciences industry. Over the last 3 years on average, earnings per share has increased by 28% per year whereas the company’s share price has increased by 30% per year.
공시 • Jul 23Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024Medpace Holdings, Inc. provided earnings guidance for the full year 2024. The company forecasts 2024 revenue in the range of $2.125 billion to $2.175 billion, representing growth of 12.7% to 15.3% over 2023 revenue of $1.886 billion. GAAP net income for full year 2024 is forecasted in the range of $361.0 million to $383.0 million. Based on forecasted 2024 revenue of $2.125 billion to $2.175 billion and GAAP net income of $361.0 million to $383.0 million, diluted earnings per share (GAAP) is forecasted in the range of $11.24 to $11.93. This guidance assumes a full year 2024 tax rate of 15.0% to 16.0%, interest income of $24.0 million, and 32.1 million diluted shares outstanding.
공시 • Jun 27Medpace Holdings, Inc. to Report Q2, 2024 Results on Jul 22, 2024Medpace Holdings, Inc. announced that they will report Q2, 2024 results After-Market on Jul 22, 2024
Reported Earnings • Apr 23First quarter 2024 earnings released: EPS: US$3.33 (vs US$2.35 in 1Q 2023)First quarter 2024 results: EPS: US$3.33 (up from US$2.35 in 1Q 2023). Revenue: US$511.0m (up 18% from 1Q 2023). Net income: US$102.6m (up 41% from 1Q 2023). Profit margin: 20% (up from 17% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 7.6% growth forecast for the Global Life Sciences industry. Over the last 3 years on average, earnings per share has increased by 28% per year whereas the company’s share price has increased by 24% per year.
공시 • Apr 23Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024Medpace Holdings, Inc. provided earnings guidance for the full year 2024. The Company forecasts 2024 revenue in the range of $2.150 billion to $2.200 billion, representing growth of 14.0% to 16.7% over 2023 revenue of $1.886 billion. GAAP net income for full year 2024 is forecasted in the range of $347.0 million to $369.0 million, diluted earnings per share (GAAP) is forecasted in the range of $10.79 to $11.47.
Board Change • Apr 15Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Director Femida Gwadry-Sridhar was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Apr 04Medpace Holdings, Inc., Annual General Meeting, May 17, 2024Medpace Holdings, Inc., Annual General Meeting, May 17, 2024, at 09:00 US Eastern Standard Time. Agenda: To elect Fred B. Davenport, Jr. and Cornelius P. McCarthy III as Class II Directors to serve until the 2027 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified; to ratify the appointment of Deloitte & Touche LLP as company independent registered public accounting firm for the fiscal year ending December 31, 2024; to conduct an advisory vote to approve compensation for our named executive officers; to approve an amendment to the company's Amended and Restated Certificate of Incorporation to begin phasing out the company's classified Board of Directors so that directors up for election at and after the 2025 Annual Meeting of Stockholders will be elected annually; and to transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment of the Annual Meeting by or at the direction of the Board of Directors of the company.
공시 • Mar 29Medpace Holdings, Inc. to Report Q1, 2024 Results on Apr 22, 2024Medpace Holdings, Inc. announced that they will report Q1, 2024 results on Apr 22, 2024
Board Change • Dec 05Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Director Femida Gwadry-Sridhar was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Oct 25Medpace Holdings, Inc. Provides Earnings Guidance for the Fiscal Year 2023 and 2024Medpace Holdings, Inc. provided earnings guidance for the fiscal year 2023 and 2024. For the year 2023, the company expects revenue in the range of $1.870 billion to $1.890 billion, representing growth of 28.1% to 29.5% over 2022 revenue of $1.460 billion. GAAP net income for full year 2023 is forecasted in the range of $272.0 million to $276.0 million and diluted earnings per share (GAAP) is forecasted in the range of $8.54 to $8.66.For the year 2024, the company expects revenue in the range of $2.150 billion to $2.200 billion.
공시 • Sep 27Medpace Holdings, Inc. to Report Q3, 2023 Results on Oct 23, 2023Medpace Holdings, Inc. announced that they will report Q3, 2023 results on Oct 23, 2023
Board Change • Sep 22Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Director Femida Gwadry-Sridhar was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Jul 26Second quarter 2023 earnings released: EPS: US$2.00 (vs US$1.52 in 2Q 2022)Second quarter 2023 results: EPS: US$2.00 (up from US$1.52 in 2Q 2022). Revenue: US$460.9m (up 31% from 2Q 2022). Net income: US$61.1m (up 24% from 2Q 2022). Profit margin: 13% (in line with 2Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Global Life Sciences industry. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth.
공시 • Jul 25Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2023Medpace Holdings, Inc. provided earnings guidance for the full year 2023. The company forecasts 2023 revenue in the range of $1.840 billion to $1.880 billion, representing growth of 26.0% to 28.8% over 2022 revenue of $1.460 billion. GAAP net income for full year 2023 is forecasted in the range of $256.0 million to $271.0 million. Based on forecasted 2023 revenue of $1.840 billion to $1.880 billion and GAAP net income of $256.0 million to $271.0 million, diluted earnings per share (GAAP) is forecasted in the range of $8.04 to $8.50.
Board Change • Jul 14Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Director Femida Gwadry-Sridhar was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Jul 06Medpace Holdings, Inc. to Report Q2, 2023 Results on Jul 24, 2023Medpace Holdings, Inc. announced that they will report Q2, 2023 results After-Market on Jul 24, 2023
공시 • Jun 25+ 1 more updateMedpace Holdings, Inc.(NasdaqGS:MEDP) dropped from Russell 2000 Growth-Defensive IndexMedpace Holdings, Inc.(NasdaqGS:MEDP) dropped from Russell 2000 Growth-Defensive Index
Board Change • May 12Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Director Femida Gwadry-Sridhar was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 28First quarter 2023 earnings released: EPS: US$2.35 (vs US$1.76 in 1Q 2022)First quarter 2023 results: EPS: US$2.35 (up from US$1.76 in 1Q 2022). Revenue: US$434.1m (up 31% from 1Q 2022). Net income: US$72.8m (up 19% from 1Q 2022). Profit margin: 17% (down from 19% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Global Life Sciences industry. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.
Board Change • Apr 26Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Director Femida Gwadry-Sridhar was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Feb 14Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2023Medpace Holdings, Inc. provided earnings guidance for the year 2023. For the year, the company expects revenue in the range of $1.690 billion to $1.750 billion, representing growth of 15.8% to 19.9% over 2022 revenue of $1.460 billion. GAAP net income is forecasted in the range of $245.0 million to $265.0 million. Based on forecasted revenue of $1.690 billion to $1.750 billion and GAAP net income of $245.0 million to $265.0 million, diluted earnings per share (GAAP) is forecasted in the range of $7.53 to $8.14.
Board Change • Jan 27Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Director Femida Gwadry-Sridhar was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Jan 05Medpace Holdings, Inc. to Report Fiscal Year 2022 Results on Feb 13, 2023Medpace Holdings, Inc. announced that they will report fiscal year 2022 results at 4:00 PM, US Eastern Standard Time on Feb 13, 2023
공시 • Jan 04Medpace Holdings, Inc. Announces Resignation of Thomas C. King to BoardOn December 31, 2022, Thomas C. King, a member of the Board of Directors of Medpace Holdings, Inc. notified the Company of his resignation from the Board, effective as of December 31, 2022. Mr. King’s resignation did not result from any disagreement with the Company on any matter relating to its operations, policies or practices.
Board Change • Dec 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. Independent Director Thomas King was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Dec 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. Independent Director Thomas King was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • Nov 18CFO & Treasurer recently sold Mex$8.8m worth of stockOn the 16th of November, Kevin Brady sold around 2k shares on-market at roughly Mex$4,423 per share. This transaction amounted to 40% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Kevin's only on-market trade for the last 12 months.
Board Change • Nov 17Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. Independent Director Thomas King was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Nov 01Investor sentiment improved over the past weekAfter last week's 37% share price gain to Mex$4,326, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 29x in the Life Sciences industry globally. Total returns to shareholders of 202% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at Mex$6,096 per share.
Reported Earnings • Oct 26Third quarter 2022 earnings released: EPS: US$2.13 (vs US$1.35 in 3Q 2021)Third quarter 2022 results: EPS: US$2.13 (up from US$1.35 in 3Q 2021). Revenue: US$383.7m (up 30% from 3Q 2021). Net income: US$66.0m (up 36% from 3Q 2021). Profit margin: 17% (in line with 3Q 2021). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Global Life Sciences industry. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 44% per year, which means it is tracking significantly ahead of earnings growth.
Board Change • Oct 25Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. Independent Director Thomas King was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Recent Insider Transactions • Sep 23Chairman & CEO recently bought Mex$292m worth of stockOn the 20th of September, August Troendle bought around 94k shares on-market at roughly Mex$3,105 per share. This transaction amounted to 1.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. August has been a buyer over the last 12 months, purchasing a net total of Mex$500m worth in shares.
Board Change • Sep 22Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Director Thomas King was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • Sep 14Chairman & CEO recently bought Mex$207m worth of stockOn the 12th of September, August Troendle bought around 63k shares on-market at roughly Mex$3,316 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was August's only on-market trade for the last 12 months.
Valuation Update With 7 Day Price Move • Sep 02Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to Mex$2,914, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 30x in the Life Sciences industry globally. Total returns to shareholders of 88% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at Mex$3,750 per share.
Board Change • Aug 18Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Director Thomas King was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Jul 26Second quarter 2022 earnings released: EPS: US$1.52 (vs US$1.11 in 2Q 2021)Second quarter 2022 results: EPS: US$1.52 (up from US$1.11 in 2Q 2021). Revenue: US$351.2m (up 26% from 2Q 2021). Net income: US$49.4m (up 24% from 2Q 2021). Profit margin: 14% (in line with 2Q 2021). Over the next year, revenue is forecast to grow 14%, compared to a 12% growth forecast for the industry in Mexico. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth.
Board Change • Jul 25Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Director Thomas King was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Jun 28Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Director Thomas King was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Jun 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Director Thomas King was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Feb 25Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to Mex$3,022, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 34x in the Life Sciences industry globally. Total loss to shareholders of 11% over the past year. Simply Wall St's valuation model estimates the intrinsic value at Mex$5,635 per share.
Recent Insider Transactions • Feb 24Lead Independent Director recently bought Mex$1.5m worth of stockOn the 17th of February, Fred Davenport bought around 500 shares on-market at roughly Mex$2,959 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold Mex$20m more in shares than they bought in the last 12 months.
Reported Earnings • Feb 16Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: US$5.07 (up from US$4.07 in FY 2020). Revenue: US$1.14b (up 23% from FY 2020). Net income: US$181.8m (up 26% from FY 2020). Profit margin: 16% (in line with FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 25%, compared to a 16% growth forecast for the pharmaceuticals industry in Mexico.
Valuation Update With 7 Day Price Move • Nov 05Investor sentiment improved over the past weekAfter last week's 21% share price gain to Mex$4,630, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 45x in the Life Sciences industry globally. Simply Wall St's valuation model estimates the intrinsic value at Mex$3,700 per share.
Reported Earnings • Oct 26Third quarter 2021 earnings released: EPS US$1.36 (vs US$1.16 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: US$295.6m (up 28% from 3Q 2020). Net income: US$48.6m (up 18% from 3Q 2020). Profit margin: 16% (down from 18% in 3Q 2020). The decrease in margin was driven by higher expenses.
Reported Earnings • Jul 28Second quarter 2021 earnings released: EPS US$1.11 (vs US$0.68 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$278.3m (up 36% from 2Q 2020). Net income: US$39.9m (up 66% from 2Q 2020). Profit margin: 14% (up from 12% in 2Q 2020). The increase in margin was driven by higher revenue.
Recent Insider Transactions • Mar 12Executive Vice President of Operations recently sold Mex$22m worth of stockOn the 3rd of March, Susan Burwig sold around 6k shares on-market at roughly Mex$3,486 per share. This was the largest sale by an insider in the last 3 months. Susan has been a seller over the last 12 months, reducing personal holdings by Mex$58m.
Recent Insider Transactions • Mar 06Executive Vice President of Operations recently sold Mex$22m worth of stockOn the 3rd of March, Susan Burwig sold around 6k shares on-market at roughly Mex$3,486 per share. This was the largest sale by an insider in the last 3 months. Susan has been a seller over the last 12 months, reducing personal holdings by Mex$58m.
Reported Earnings • Feb 19Full year 2020 earnings released: EPS US$4.07 (vs US$2.79 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: US$925.9m (up 7.5% from FY 2019). Net income: US$144.9m (up 45% from FY 2019). Profit margin: 16% (up from 12% in FY 2019). The increase in margin was driven by higher revenue.
Analyst Estimate Surprise Post Earnings • Feb 19Revenue beats expectationsRevenue exceeded analyst estimates by 1.5%. Over the next year, revenue is forecast to grow 23%, compared to a 44% growth forecast for the Life Sciences industry in Mexico.
Valuation Update With 7 Day Price Move • Feb 13Investor sentiment improved over the past weekAfter last week's 21% share price gain to US$3,345, the stock is trading at a trailing P/E ratio of 48.2x, up from the previous P/E ratio of 39.9x. This compares to an average P/E of 55x in the Life Sciences industry. Total returns to shareholders over the past year are 106%.